TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: breast-cancer mortality
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge gains
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Informed decisions about starting KT evaluation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Informed decisions about pursuing DDKT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Informed decisions about pursuing LDKT
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of children with serum 25(OH)D ≥50 nmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of combination treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downtime
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Time of recovery of gastrointestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of first passage of gas by anus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Variceal pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total daily energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful treatment of thin capped fibroatheroma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall accuracy of transthoracic sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance of tasks associated with flying ability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fat mass decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSV A and B microneutralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-F IgG titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: palivizumab competitive antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Risk of coronary heart disease (CHD)
Endpoint domain: Mortality/survival
Primary endpoint: response rate of patients with vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dislodgment rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lead malfunction rates
Endpoint domain: Adverse events/effects
Primary endpoint: SHA ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemostatic efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: annualised bleeding events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement on nonfatal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Agreement on fatal outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of immune reconstitution inflammatory syndrome (IRIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality (deaths due to IRIS)
Endpoint domain: Mortality/survival
Primary endpoint: Hepatitis B virus DNA (HBV‐DNA) negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion of HBeAg to anti‐HBe
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative myocardial ischaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endurance times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of inspiratory muscles (RMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Borg rating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in body mass index z-scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of local anesthetic used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: crowding alleviation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VRS scores for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive predictive value of chest sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of chest sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of chest sonography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue antiemetic therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean antiemetic drug cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain scores during venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores 30 seconds after venipuncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔE at Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area of re-epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in keratinized tissue (KTW)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rates of vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractal HR behavior during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Alpha1 at supine rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: survival time for discontinuation for any reason
Endpoint domain: Mortality/survival
Primary endpoint: mood symptom ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to pain with oesophageal acid infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likert scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough platelet COX‐1‐derived serum Tx B2 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean antipsychotic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concurrent use of more than one antipsychotic drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of antiparkinson medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in 1-RM squat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gains in bench press
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in DEXA-derived android/gynoid ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission from symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pedicle perforation rate
Endpoint domain: Adverse events/effects
Primary endpoint: Screw insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: C-arm movement frequency
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: behavioral response to methylphenidate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: multiple organ dysfunction score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating BCAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median length of stay postsurgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Estimated blood loss (EBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent oral feeding attainment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for intravenous antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean plaque index reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants reporting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Falls and injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Suicidal ideation
Endpoint domain: Adverse events/effects
Primary endpoint: Intravitreal functional plasminogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravitreal VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MIP (Maximum Inspiratory Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Muscular endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of spirometry parameters (FEV(1), PEF, FEF(25‐75%))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bond failure rate
Endpoint domain: Mortality/survival
Primary endpoint: incidence of severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of severe mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GEARS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MIQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMD-17 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stool weight (g/kg b.w.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: RH%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tPA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological result detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with grade >/=2 neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of cycles with grade >/=2 neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Fibrosis of the anterior capsule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Membrane growth from the rhexis edge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plasma antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in vitamin C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: increase in plasminogen activator inhibitor 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial hypotension incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean accumulated ephedrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensory block regression time to T12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to try a cigarette
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Helping others quit
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Attitudes about the drug effects of smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in non-HDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptoms of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narcotic analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: acute success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complications (AV-block I-II degree)
Endpoint domain: Adverse events/effects
Primary endpoint: Risk of AMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: changes in fasting serum hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean percent improvements in total symptom complex severity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PONV (nausea and vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WMFT-FA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAL-AOU improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAL-QOM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cognition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb rise greater than or equal to 2.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb rise greater than or equal to 3.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb greater than 12.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of dying before the next follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Global health status and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Blood antioxidant capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lipid peroxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to clinical stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management plans changed following invasive urodynamic testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pref‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease of crying duration
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of grade 2 or more stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Time to grade 2 or more stomatitis
Endpoint domain: Adverse events/effects
Primary endpoint: itching intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of crowns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of developing heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shear bond strengths of orthodontic brackets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAB‐S Medication Tolerability scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean depressive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self management of chronic disease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of VAP
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced akathisia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of tardive dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isokinetic peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total work
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall continence improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in IOP at 17:00 at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percent change in IOP at 17:00 at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Distribution of subjects with percentage decrease of IOP > 30%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: CDRS-R score decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG cellular influx rate constant (Ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to first treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vision-related quality-of-life impairment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean daytime DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of thirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort from thirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal shift occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant improvement following individualized treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term survival outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Circulating Hb(Fe)-NO, R-SNO, and FENO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of nebulized sodium nitrite
Endpoint domain: Adverse events/effects
Primary endpoint: Total accuracy of sensitivity and specificity for smoking detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of rescue narcotic medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: N400 anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LPC amplitude reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average and maximum dyskinesia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating levels of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Snoring index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: search scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confidence in using MEDLINE
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HF hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cuff pressure pain tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression of early idiopathic scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exacerbation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: sputum purulence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Combined end point of stroke or vascular death
Endpoint domain: Mortality/survival
Primary endpoint: LES resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time percentage with esophageal pH <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of culture-proven CONS in children with cerebral palsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Development of severe heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined end-points (cardiovascular death, myocardial infarction, or severe heart failure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HPV‐18 detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: risk of HPV‐18 ASC‐US+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: risk of 12MPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Abuse quotient (Cmax/Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes